Quince Therapeutics Q3 2026 Earnings Date & Estimates

Quince Therapeutics (NASDAQ:QNCX) (NASDAQ:QNCX) is a clinical-stage biotechnology company developing therapies for rare and debilitating diseases. The company focuses on precision medicines designed to address underlying disease mechanisms and unmet medical needs in patient populations that may have limited treatment options.

Quince’s pipeline includes efzofitimod, an investigational immunomodulator being developed for pulmonary sarcoidosis, a rare inflammatory disease that can affect lung function. The company is also advancing an erythrocyte-based drug-delivery platform, known as EryDex, which is designed to use a patient’s red blood cells to deliver therapeutic compounds. Its lead EryDex-based program is being evaluated for ataxia-telangiectasia, a rare inherited neurodegenerative disorder.

The company was formerly known as Cortexyme, Inc. and adopted the Quince Therapeutics name as it shifted its strategic focus toward rare-disease therapeutics. Its research and clinical programs are intended for patients in the United States and international markets, subject to regulatory approval. Quince is headquartered in California and conducts development activities through collaborations and clinical studies in multiple regions.